Prospect: Information for the User
INVEGA 3 mg prolonged-release tablets
INVEGA 6 mg prolonged-release tablets
INVEGA 9 mg prolonged-release tablets
INVEGA 12 mg prolonged-release tablets
Paliperidone
Read this prospect carefully before starting to take the medicine because it contains important information for you.
1. What INVEGA is and for what it is used
2. What you need to know before starting to take INVEGA
3. How to take INVEGA
4. Possible adverse effects
5. Storage of INVEGA
6. Contents of the pack and additional information
INVEGA contains the active ingredient paliperidone, which belongs to the class of antipsychotic medications.
INVEGA is used to treat schizophrenia in adults and adolescents 15 years of age and older.
Schizophrenia is a disorder that causes symptoms that include hearing, seeing, or feeling things that do not exist, holding false beliefs, having an abnormal distrust, becoming withdrawn, speaking incoherently, and flattening of behavior and emotion. People with this disorder may also feel depressed, anxious, guilty, or tense.
INVEGA is also used to treat schizoaffective disorder in adults.
Schizoaffective disorder is a mental condition in which a person experiences some of the symptoms of schizophrenia (listed in the previous paragraph) in addition to mood disorder symptoms (feeling elated, sad, agitated, distracted, insomnia, loquaciousness, loss of interest in daily activities, excessive or inadequate sleep, excessive or inadequate food intake, and recurring thoughts of suicide).
INVEGA may help alleviate the symptoms of your illness and prevent them from recurring.
Do not take INVEGA
-if you are allergic to paliperidone, risperidone, or any of the other ingredients in this medication (listed in section 6)
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take INVEGA.
If you have any of these conditions, please consult your doctor as it may be necessary to adjust your dose or keep you under observation for a period of time.
Because in very rare cases, a dangerously low number of a type of white blood cell necessary to fight infections in the blood has been observed in patients treated with INVEGA, your doctor may check your white blood cell count.
INVEGA may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with INVEGA, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed. Your doctor should check for signs of increased blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not dilate as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery and this may cause eye damage. If you are planning to have eye surgery, be sure to inform your ophthalmologist that you are taking this medication.
Children and adolescents
INVEGA should not be administered to children and adolescents under 15 years of age for the treatment of schizophrenia.
INVEGA should not be administered to children and adolescents under 18 years of age for the treatment of schizoaffective disorder.
This is because it is unknown whether INVEGA is safe or effective in this age group.
INVEGA with other medications
Inform your doctor or pharmacist if you are using or have recently used other medications.
Abnormalities in heart function may occur when this medication is taken with other medications for heart rhythm control or other medications such as antihistamines, antimalarials, or antipsychotics.
Since this medication primarily acts on the brain, this medication may interfere with other medications (or alcohol) that also act on it, due to the cumulative effect on brain function.
This medication may lower blood pressure, so you should be careful if you take this medication with other medications that also lower blood pressure.
This medication may reduce the effect of medications for Parkinson's disease and restless leg syndrome (e.g., levodopa).
The effects of this medication may be affected if you take medications that influence the speed of intestinal movement (e.g., metoclopramide).
Reduction of this medication dose should be considered when this medication is administered with valproate.
The use of oral risperidone with this medication is not recommended as this combination may cause an increase in adverse effects.
INVEGA with alcohol
You should avoid consuming alcohol during treatment with this medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
You should not take this medication during pregnancy unless you have discussed it with your doctor.
The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last three months of pregnancy (last trimester): tremor, rigidity, and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, contact your doctor.
You should not take this medication during breastfeeding.
Driving and operating machinery
During treatment with this medication, dizziness and vision problems (see section 4, Possible side effects) may occur. This should be taken into account when requiring maximum attention, for example, when driving or operating machinery.
The 3 mg INVEGA tablet contains lactose
The 3 mg tablet of this medication contains lactose, a type of sugar. If your doctor has told you that you are intolerant to some sugars, speak with them before taking this medication.
INVEGA contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per dose; this is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor, pharmacist, or nurse.
Use in adults
The recommended dose in adults is 6 mg once a day in the morning. Your doctor may increase or decrease it within the dosing interval of 3 mg to 12 mg once a day in the case of schizophrenia or 6 mg to 12 mg once a day in the case of schizoaffective disorder. This depends on how well the medication works for you.
Use in adolescents
The recommended starting dose for the treatment of schizophrenia in adolescents 15 years of age or older is 3 mg once a day taken in the morning.
For adolescents weighing 51 kg or more, the dose may be increased within the interval of 6 mg to 12 mg once a day.
For adolescents weighing less than 51 kg, the dose may be increased to 6 mg once a day.
Your doctor will decide how much to administer to you. The amount you take depends on how well the medication works for you.
How and when to take INVEGA
This medication should be taken by mouth, swallowed whole with water or other liquids. Do not chew, break, or crush.
This medication should be taken in the mornings with breakfast or on an empty stomach, but every day in the same way. Do not alternate between taking the medication one day with breakfast and the next day on an empty stomach.
The active ingredient, paliperidone, dissolves once swallowed, and the coating of the tablet is eliminated from the body through the feces.
Patients with kidney problems
Your doctor may adjust your dose of this medication according to your renal function.
Seniors
Your doctor may reduce your medication dose if your renal function is reduced.
If you take more INVEGA than you should
Contact your doctor immediately. You may experience drowsiness, fatigue, abnormal body movements, difficulty staying upright and walking, dizziness due to reduced blood pressure, and alterations in heartbeats.
If you forgot to take INVEGA
Do not take a double dose to compensate for the missed doses. If you forget a dose, take the next dose the following day. If you forget two or more doses, contact your doctor.
If you interrupt treatment with INVEGA
Do not stop taking this medication as you will lose the effects of the medication. Do not stop taking this medication unless your doctor tells you to, as your symptoms may return.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if:
Very common: may affect more than 1 in 10 patients
Common side effects:may affect up to 1 in 10 patients
Rare side effects: may affect up to 1 in 100 patients
Rare side effects: may affect up to 1 in 1,000 patients
Unknown: their frequency cannot be estimated from available data
The following side effects have appeared with the use of another medication called risperidone, which is very similar to paliperidone, so it is also expected to appear with INVEGA: eating disorder related to sleep, other types of brain blood vessel problems, and lung crepitus sounds. Other eye problems may also appear during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) may occur if you are taking or have taken INVEGA. If you need to undergo cataract surgery, make sure to inform your ophthalmologist if you are taking or have taken this medication.
Additional side effects in adolescents
Adolescents generally experienced side effects similar to those found in adults, except for the following side effects that were detected more frequently:
• Feeling drowsy or less attentive
•Parkinsonism: This disease can include slow or altered movement, a feeling of stiffness or tension in the muscles (making sudden movements), and sometimes a feeling of "freezing" of movement that is then restarted. Other signs of parkinsonism include walking slowly with dragging feet, trembling while resting, increased saliva and/or drooling, and loss of facial expression.
• Weight gain
• Common cold symptoms
• Restlessness
• Tremor (agitation)
• Abdominal pain
• Milk secretion by the breasts in girls
• Swollen breasts in boys
• Acne
• Speech problems
• Stomach or intestinal infection
• Nasal bleeding
• Ear infection
• High triglycerides in the blood (a type of fat)
• Feeling of spinning (vertigo).
Reporting side effects
If you experience side effects, consult your doctor, pharmacist, or nurse, even if they do not appear in this leaflet. You can also report them directly through thenational reporting system included in theAppendix V.Mby reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister/container and on the box after EXP. The expiration date is the last day of the month indicated.
Containers: Do not store at a temperature above 30°C. Keep the container perfectly closed to protect it from moisture.
Blister packs: Do not store at a temperature above 30°C. Store in the original packaging to protect it from moisture.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medication that you no longer need. By doing so, you will help protect the environment.
Composition of INVEGA
The active ingredient is paliperidone.
Each prolonged-release tablet of 3 mg of INVEGA contains 3 mg of paliperidone.
Each prolonged-release tablet of 6 mg of INVEGA contains 6 mg of paliperidone.
Each prolonged-release tablet of 9 mg of INVEGA contains 9 mg of paliperidone.
Each prolonged-release tablet of 12 mg of INVEGA contains 12 mg of paliperidone.
The other components are:
Tablet core:
Polysorbate 80
Sodium chloride Povidone (K29-32)
Stearic acid
BHT (E321)
Iron oxide (Yellow) (E172) (only in 3 mg and 12 mg tablets)
Polysorbate 80
Iron oxide (Red) (E172)
Hydroxyethyl cellulose
Poloxamer 3350
Cellulose acetate
Iron oxide (Black) (E172) (only in 9 mg tablets)
Colored coating: Hypromellose
Titanium dioxide (E171)
Poloxamer 400 (only in 6, 9, and 12 mg tablets)
Iron oxide (Yellow) (E172) (only in 6 and 12 mg tablets)
Iron oxide (Red) (E172) (only in 6 and 9 mg tablets)
Lactose monohydrate (only in 3 mg tablets)
Triacetin (only in 3 mg tablets)
Carnauba wax
Printing ink:
Iron oxide (Black) (E172) Propylene glycol
Hypromellose
Appearance of the product and contents of the pack
INVEGA prolonged-release tablets are capsule-shaped. The 3 mg tablets are white and engraved with “PAL 3”, the 6 mg tablets are beige and engraved with “PAL 6”, the 9 mg tablets are pink and engraved with “PAL 9”, and the 12 mg tablets are dark yellow and engraved with “PAL12”. All tablets are available in the following pack sizes:
Only some pack sizes may be marketed.
Marketing Authorization Holder
Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse
BelgiumManufacturer
Janssen-Cilag SpA Via C. Janssen
04100 Borgo San Michele
Latina
Italy
For further information about this medicinal product, please consult the representative of the marketing authorization holder in your country:
| Lietuva UAB “JOHNSON & JOHNSON” Tel: +370 5 278 68 88 | |
| Luxembourg/Luxemburg Janssen-Cilag NV Tél:+32 14 64 94 11 | |
| Magyarország JANSSEN-CILAG Kft. Tel.: +36 1 884 2858 | |
| Malta AM MANGION LTD. Tel: +356 2397 6000 | |
| Nederland JANSSEN-CILAG B.V. Tel: +31 76 711 1111 | |
| Norge JANSSEN-CILAG AS Tlf: +47 24 12 65 00 | |
Ελλ?δα JANSSEN-CILAG Φαρμακευτικ? Α.Ε.Β.Ε Tηλ: +30 210 80 90 000 | Österreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 | |
| Polska JANSSEN–CILAG Polska Sp. z o.o. Tel.: +48 22 237 60 00 | |
| Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 | |
| România Johnson & JohnsonRomânia SRL Tel: +40 21 207 1800 | |
| Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 | |
| Slovenská republika Johnson & Johnson, s.r.o. Tel: +421 232 408 400 | |
| Suomi/Finland JANSSEN-CILAG OY Puh/Tel: +358 207 531 300 | |
| Sverige JANSSEN-CILAG AB Tel: +46 8 626 50 00 | |
| United Kingdom JANSSEN-CILAG Ltd. Tel: +44 1 494 567 444 |
Last update of the summary of product characteristics: MM/AAAA
Other sources of information
Further information on this medicinal product is available on the website of the European Medicines Agency
http://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.